Epilogue

Abstract

In an attempt to attenuate the pathologic effects of cardiopulmonary bypass (CPB), miniaturised extracorporeal circulation (MECC) systems have been developed to allow the ease of on-pump heart surgery while tempering the disadvantages from the CPB use. The idea of MECC systems has initiated important new efforts within science and industry to improve the biocompatibility of CPB systems and hence minimise their side effects as well as offer better global organ protection. To meet this goal, MECC has integrated in the system a centrifugal blood pump with optimal biocompatibility, especially low thrombogenicity, reduced haemolysis and activation of leukocytes as well as mediators; minimised components to reduce the priming volume, thus hemodilution and less need for donor blood. The system was designed to provide access to all coronary regions as well as to intracardiac structures; temperature management of the different forms of normothermia or hypothermia depending on the need is possible; safe de-airing procedures for open-heart surgery are possible. Finally, it is of paramount importance that MECC supports modern concept of fast-track anaesthesia.